Press Release
<< Back
Verastem to Present Preclinical Data at the 2015 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
The details for the poster presentations at AACR-NCI-EORTC are as follows:
Title: FAK/PYK2 Inhibitors Defactinib and VS-4718 Enhance Immune
Checkpoint Inhibitor Efficacy
Date and time:
Location: Exhibit Hall C-D
Session
info: Tumor Immunology Targets
Abstract ID: A191
Title: Focal Adhesion Kinase Inhibition Enables Efficacy of
Checkpoint Immunotherapy in Pancreatic Cancer
Date and time:
Location: Exhibit
Hall C-D
Session info: Tumor Microenvironment
Abstract
ID: B197
Title: FAK Inhibition Induces T Cell-mediated Tumor Regression: A
Novel Role for Nuclear FAK in Controlling Tregs via Transcription of
Cytokine Networks
Date and time:
Location: Exhibit Hall C-D
Session
info: Tumor Immunology Targets
Abstract ID: A189
Title: FAK Inhibition Targets Cancer Stem Cells
Date and
time:
Location:
Exhibit Hall C-D
Session info: Cancer Stem Cells
Abstract
ID: C29
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the “Window of Opportunity” study in patients with mesothelioma prior to surgery, a Phase 1/1b study in combination with paclitaxel in patients with ovarian cancer, a trial in patients with KRAS-mutated non-small cell lung cancer and a trial evaluating the combination of VS-6063 and VS-5584 in patients with relapsed mesothelioma.
About VS-4718
VS-4718 is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). VS-4718 is currently being studied in a Phase 1 dose escalation study in patients with advanced cancers.
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development and activity of the Company’s product
candidates, VS-6063 and VS-4718, and the Company’s FAK program
generally, and the potential for combination of FAK inhibitors with
immuno-oncology agents. The words “anticipate,” “appear,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks and
uncertainties include the risks that the preclinical testing of the
Company’s product candidates and preliminary or interim data from
clinical trials may not be predictive of the results or success of
ongoing or later clinical trials, that data may not be available when we
expect it to be, that enrollment of clinical trials may take longer than
expected, that our product candidates will cause unexpected safety
events, that the Company will be unable to successfully initiate or
complete the clinical development of its product candidates, that the
development of the Company’s product candidates will take longer or cost
more than planned, and that the Company’s product candidates will not
receive regulatory approval or become commercially successful products.
Other risks and uncertainties include those identified under the heading
“Risk Factors” in the Company’s Annual Report on Form 10-K for the year
ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20151027005940/en/
Source:
Contact Verastem, Inc.:
Brian Sullivan, 781-292-4214
bsullivan@verastem.com
